The abstract is read at the publisher; the summary is JClub's.
In HDM-allergic nasal epithelium, PAR2 up-regulation and epithelium-specific TRPV4 up-regulation are linked to tight-junction changes, and PAR2–TRPV4 signaling drives barrier dysfunction.
- Why it matters: Current allergic rhinitis therapies address inflammation more than epithelial barrier failure, and HDM allergy is a key context where the underlying receptor crosstalk is unclear.
- What they did: In 30 allergic rhinitis patients and 30 controls (including 10 HDM-sensitized), the study used qRT-PCR, immunostaining, western blotting, and a Der p 1 epithelial model with calcium imaging, mutagenesis, and transepithelial electrical resistance, plus OVA- and HDM-induced mouse models and PAR2/TRPV4 antagonists.
- The result: TRPV4 inhibition blocked PAR2-mediated barrier disruption, and a PKCε–Ca2+–TRPV4 positive feedback loop requiring TRPV4 Y110 supported sustained calcium influx; PAR2 or TRPV4 inhibition restored barrier function, with dual antagonism most effective in HDM-induced allergic rhinitis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.